(NaturalNews) Angelina Jolie's announcement of undergoing a double mastectomy (surgically removing both breasts) even though she had no breast cancer is not the innocent, spontaneous, "heroic choice" that has been portrayed in the mainstream media. Natural News has learned it all coincides with a well-timed for-profit corporate P.R. campaign that has been planned for months and just happens to coincide with the upcoming U.S. Supreme Court decision on the viability of the BRCA1 patent.
This is the investigation the mainstream media refuses to touch. Here, I explain the corporate financial ties, investors, mergers, human gene patents, lawsuits, medical fear mongering and the trillions of dollars that are at stake here. If you pull back the curtain on this one, you find far more than an innocent looking woman exercising a "choice." This is about protecting trillions in profits through the deployment of carefully-crafted public relations campaigns designed to manipulate the public opinion of women.
The signs were all there from the beginning of the scheme: Angelina Jolie's highly polished and obviously corporate-written op-ed piece at the New York Times, the carefully-crafted talking points invoking "choice" as a politically-charged keyword, and the obvious coaching of even her husband Brad Pitt who carefully describes the entire experience using words like "stronger" and "pride" and "family."
But the smoking gun is the fact that Angelina Jolie's seemingly spontaneous announcement magically appeared on the cover of People Magazine this week -- a magazine that is usually finalized for publication three weeks before it appears on newsstands. That cover, not surprisingly, uses the same language found in the NYT op-ed piece: "HER BRAVE CHOICE" and "This was the right thing to do." The flowery, pro-choice language is not a coincidence.
What this proves is that Angelina's Jolie's announcement was a well-planned corporate P.R. campaign with carefully-crafted messages designed to influence public opinion. But what could Jolie be seeking to influence?
...how about trillions of dollars in corporate profits?
Upcoming U.S. Supreme Court decision to rule on patent viability for BRCA1 gene
Angelina Jolie's announcement and all its carefully-crafted language had four notable immediate impacts:
1) It caused women everywhere to be terrified of breast cancer through the publishing of false statistics that drove fear into the hearts of anyone with breasts. (See below for explanation.)
2) It caused women to rush out and seek BRCA1 gene testing procedures. These tests just happen to be patented by a for-profit corporation called "Myriad Genetics." Because of this patent, BRCA1 tests can cost $3,000 - $4,000 each. The testing alone is a multi-billion-dollar market, but only if the patent is upheld in an upcoming Supreme Court decision (see below).
3) It caused the stock price of Myriad Genetics (MYGN) to skyrocket to a 52-week high. "Myriad's stock closed up 3% Tuesday, following the publication of the New York Times op-ed," wrote Marketwatch.com.
4) It drove public opinion to influence the upcoming U.S. Supreme Court decision to rule in favor of corporate ownership of human genes (see more below).
Women all over the world are being duped into supporting Angeline Jolie, having no idea that what she's really doing is selling out women to the for-profit cancer industry. But to fully understand what's happening, you have to dig deeper...
Myriad Genetics sees stock price skyrocket thanks to Jolie, and Obamacare will funnel billions their way
"Salt Lake City-based Myriad Genetics (MYGN) holds the patent on the test that determined the actress had an 87% chance of developing breast cancer, as well as the genes themselves," wrote MarketWatch.com.
And that's only the beginning. If the U.S. Supreme Court can be influenced to uphold Myriad's patent, it could mean a trillion-dollar industry over just the next few years. Even more, Myriad Genetics is reportedly "ripe for mergers" according to the financial press, because it's part of the super-hot human genome industry.
"The world's largest maker of DNA testing and analysis tools, Life Technologies Corp. said that it is set to be acquired by Thermo Fisher Scientific for a record $13.6 billion," writes MarketWatch.com. "A race that kicked into high gear more than 26 years ago is heating up, with foreign governments and corporations joining the U.S. in funding the quest to map all the human genomes. And even as the recent flurry of mergers and acquisitions in the genomics space has spurred returns, investors still have opportunities to profit from this multibillion-dollar industry."
The higher Myriad's stock price goes, the more profitable a merger becomes for its current owners. So Jolie's P.R. stunt just happened to generate unknown millions of dollars in value for the very people who claim a patent monopoly over the breast cancer genes residing in the bodies of women. Coincidence? Hardly.
Obamacare mandates taxpayers pay for BRCA gene testing: yet another government handout to wealthy corporations
But here's what's even more crooked about all this: You know how Obama likes to talk "free market" but actually engages in so-called "crony capitalism" by handing out money to all his corporate buddies, Wall Street insiders and deep-pocketed campaign donors? Part of Obamacare -- the "Affordable Care Act" -- mandates that taxpayers pay for BRCA1 genetic testing!
Myriad Genetics, in other words, stands to receive a full-scale windfall of profits mandated by government and pushed into mainstream consciousness through a campaign of "medical terror" fronted by Angelina Jolie and the New York Times. Are you starting to see how this all fits together yet?
This is all one big coordinated corporate sellout of women, and it's all being hidden by playing the "women's power" card and using "choice" language to more easily manipulate women. Angelina Jolie, remember, is a key spokesperson for the United Nations, an organization already caught engaged in child sex slavery and drug running. Although Jolie obviously isn't engage in that sort of behavior, her job is to covertly influence American women into supporting a carefully-planned, plotted and executed corporate profit campaign that turns women's bodies into profits.